narsoplimab

Generic: Narsoplimab·Code: OMS721

narsoplimab: developed by 1 company · 1 clinical trial tracked · 2 FDA decisions. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
OMEROS CORP (OMER)Phase 2

Clinical Trials (1)

Single Patient Expanded Access Treatment Plan (EAP; Also Known As A Compassionate Use Plan) To Provide Patients Access To The Investigational Product Narsoplimab

NCT04247906·OMER
Approved for marketing

FDA Decisions

PDUFATA-TMA in the European Union(OMER)
FDA_MeetingThe FDA accepted for review the resubmission of the Biologics License Application for narsoplimab for the treatment of HSCT-TMA.(OMER)

Frequently asked questions

Who is developing narsoplimab?

narsoplimab is being developed by OMEROS CORP.

How many clinical trials involve narsoplimab?

BioSniper tracks 1 clinical trial involving narsoplimab.

What is narsoplimab's latest FDA decision?

The most recent tracked FDA decision for narsoplimab is PDUFA for TA-TMA in the European Union, dated December 26, 2025.

Get deeper analysis on narsoplimab

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    narsoplimab — Drug Pipeline, Trials & FDA Status | BioSniper